Preliminary results suggest certolizumab pegol plus methotrexate is effective in reducing signs and symptoms of rheumatoid arthritis in patients refractory to methotrexate. Results from the RAPID 1 Study.

Authors
Category Primary study
Year 2007
This article has no abstract
Epistemonikos ID: 86cb66964a1754bfef0852b26851dcaf8c0ca185
First added on: Nov 02, 2017